ArticleInternational journal of medical sciences2017
Selective Killing of Melanoma Cells With Non-Thermal Atmospheric Pressure Plasma and p-FAK Antibody Conjugated Gold Nanoparticles.
Article in International journal of medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.Antioxidants (Basel, Switzerland) · 2025Review
- Gold nanostructures in melanoma: Advances in treatment, diagnosis, and theranostic applications.Heliyon · 2024Review
- Anti-Inflammatory Activity of No-Ozone Cold Plasma inInternational journal of molecular sciences · 2024Article
- Medical Gas Plasma Technology Combines with Antimelanoma Therapies and Promotes Immune-Checkpoint Therapy Responses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Possible Synergies of Nanomaterial-Assisted Tissue Regeneration in Plasma Medicine: Mechanisms and Safety Concerns.Nanomaterials (Basel, Switzerland) · 2022Review
- Anti-Cancer Activity of the Combinational Treatment of Noozone Cold Plasma with p-FAK Antibody-Conjugated Gold Nanoparticles in OSCC Xenograft Mice.Biomedicines · 2022Article
- Biological Risk Assessment of Three Dental Composite Materials following Gas Plasma Exposure.Molecules (Basel, Switzerland) · 2022Article
- Enhancement of Osteoblast Differentiation Using No-Ozone Cold Plasma on Human Periodontal Ligament Cells.Biomedicines · 2021Article
- Recent Advances in Nanotechnology for the Treatment of Melanoma.Molecules (Basel, Switzerland) · 2021Review
- Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication.Oxidative medicine and cellular longevity · 2021Review
- Protective Activity of Aspirin Eugenol Ester on Paraquat-Induced Cell Damage in SH-SY5Y Cells.Oxidative medicine and cellular longevity · 2021Article
- Article
- Nanosystems for Improved Targeted Therapies in Melanoma.Journal of clinical medicine · 2020Review
- Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.Journal of inorganic biochemistry · 2019Review
- Plasma and Nanomaterials: Fabrication and Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2019Review
- Melanoma treatment: from conventional to nanotechnology.Journal of cancer research and clinical oncology · 2018Review
- Apoptotic Impact of Heliox Cold Plasma on a Cervical Cell Line Using Gold Nanoparticle-Doped Graphene Oxide Nanosheets.Iranian journal of pharmaceutical research : IJPRArticle
- A Review on the Application and Mechanism of Low Temperature Plasma in the Field of Tumor Therapy.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanomas are fast growing high-mortality tumors, and specific treatments for melanomas are needed. Melanoma cells overexpress focal adhesion kinase (FAK) compared to normal keratinocytes, and we sought to exploit this difference to create a selectively lethal therapy. We combined gold nanoparticles (GNP) with antibodies targeting phosphorylated FAK (p-FAK). These conjugates (p-FAK-GNP) entered G361 melanoma cells and bound p-FAK. Treatment with p-FAK-GNP decreased the viability of G361 cells in a time dependent manner by inducing apoptosis. To maximize the preferential killing of G361 cells, non-thermal atmospheric pressure plasma was used to stimulate the GNP within p-FAK-GNP. Combined treatment with plasma and p-FAK-GNP showed much higher lethality against G361 cells than HaCaT keratinocyte cells. The p-FAK-GNP induced apoptosis over 48 hours in G361 cells, whereas plasma and p-FAK-GNP killed G361 cells immediately. This study demonstrates that combining plasma with p-FAK-GNP results in selective lethality against human melanoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.